Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome

Nature Communications

Volumn 8, Issue , 2017, Pages

  Cohen, Andrea J ^a   Saiakhova, Alina ^a   Corradin, Olivia ^a,b   Luppino, Jennifer M ^a   Lovrenert, Katreya ^a   Bartels, Cynthia F ^a   Morrow, James J ^a   Mack, Stephen C ^c   Dhillon, Gursimran ^a   Beard, Lydia ^d   Myeroff, Lois ^d   Kalady, Matthew F ^c,d   Willis, Joseph ^a,d,e   Bradner, James E ^f,g   Keri, Ruth A ^a,d   Berger, Nathan A ^a,d,e   Pruett Miller, Shondra M ^h   Markowitz, Sanford D ^a,d,e   Scacheri, Peter C ^a,c,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COHESIN; TRANSCRIPTION FACTOR AP 1;

CANCER; CELLS AND CELL COMPONENTS; GENE; GENE EXPRESSION; GENOME; GROWTH; MUTATION; SURVIVAL; TUMOR;

ARTICLE; CANCER RECURRENCE; CANCER RISK; CHROMATIN; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; CRISPR CAS SYSTEM; ENHANCER REGION; EPIGENETICS; FEMALE; GENE ACTIVATION; GENE EDITING; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MODEL; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; INFORMATION PROCESSING; METABOLISM; MORTALITY; MOUSE; MUTATION; NUDE MOUSE; PROCEDURES; TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DATASETS AS TOPIC; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HUMANS; MICE; MICE, NUDE; MUTATION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR AP-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85011876453     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14400     Document Type: Article

References (78)

1. Heintzman, N. D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311-318 (2007).
2. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
3. Akhtar-Zaidi, B. et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 336, 736-739 (2012).
4. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
5. Lovén, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).
6. Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777-790 (2013).
7. Yao, L., Tak, Y. G., Berman, B. P. & Farnham, P. J. Functional annotation of colon cancer risk SNPs. Nat. Commun. 5, 5114 (2014).
8. Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317-330 (2015).
9. Lin, C. Y. et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 530, 57-62 (2016).
10. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
11. Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity. Nat. Commun. 6, 8971 (2015).
12. Anders, S., Simon, A. & Wolfgang, H. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
13. Corradin, O. et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 24, 1-13 (2014).
14. Factor, D. C. et al. Epigenomic comparison reveals activation of 'seed' enhancers during transition from naive to primed pluripotency. Cell Stem Cell 14, 854-863 (2014).
15. Corradin, O. et al. Modeling disease risk through analysis of physical interactions between genetic variants within chromatin regulatory circuitry. Nat. Genet. 48, 1313-1320 (2016).
16. He, T. C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 (1998).
17. Zhou, L. et al. Common genetic variant on BMP4 contributes to colorectal adenoma and cancer: a meta-analysis based on 15 studies. Cytokine 72, 154-159 (2015).
18. Lubbe, S. J. et al. Evaluation of germline BMP4 mutation as a cause of colorectal cancer. Hum. Mutat. 32, E1928-E1938 (2011).
19. Zhao, P. O., Li, X., Lu, Y. & Liu, L. Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma. Oncol. Lett. 10, 895-900 (2015).
20. Zhao, P., Lu, Y. & Liu, L. Correlation of decreased expression of PHLDA1 protein with malignant phenotype of gastric adenocarcinoma. Int. J. Clin. Exp. Pathol. 8, 5230-5235 (2015).
21. Yeh, I., McCalmont, T. H. & LeBoit, P. E. Differential expression of PHLDA1 (TDAG51) in basal cell carcinoma and trichoepithelioma. Br. J. Dermatol. 167, 1106-1110 (2012).
22. Guezguez, A. et al. Modulation of stemness in a human normal intestinal epithelial crypt cell line by activation of the WNT signaling pathway. Exp. Cell Res. 322, 355-364 (2014).
23. Shi, Z. et al. Context-specific role of SOX9 in NF-Y mediated gene regulation in colorectal cancer cells. Nucleic Acids Res. 43, 6257-6269 (2015).
24. Bruun, J. et al. Prognostic significance of b2-catenin, E-cadherin, and SOX9 in colorectal cancer: results from a large population-representative series. Front. Oncol. 4, doi: 10.3389/fonc.2014.00118 (2014).
25. Panza, A. et al. Interplay between SOX9, b-catenin and PPARg activation in colorectal cancer. Biochim. Biophys. Acta 1833, 1853-1865 (2013).
26. Salazar, M. et al. Oncosuppressive functions of tribbles pseudokinase 3. Biochem. Soc. Trans. 43, 1122-1126 (2015).
27. Stein, S. J., Mack, E. A., Rome, K. S. & Pear, W. S. Tribbles in normal and malignant haematopoiesis. Biochem. Soc. Trans. 43, 1112-1115 (2015).
28. Kaneda, H. et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res. 70, 2053-2063 (2010).
29. Li, T. et al. miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. Biotechnol. Lett. 36, 1743-1752 (2014).
30. Pusapati, R. V., Weaks, R. L., Rounbehler, R. J., McArthur, M. J. & Johnson, D. G. E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol. Carcinog. 49, 152-156 (2010).
31. Sebastián, C. et al. The histone deacetylase SIRT6 Is a tumor suppressor that controls cancer metabolism. Cell 151, 1185-1199 (2012).
32. Zhu, J. et al. Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell 152, 642-654 (2013).
33. Yan, J. et al. Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell 154, 801-813 (2013).
34. Ing-Simmons, E. et al. Spatial enhancer clustering and regulation of enhancer-proximal genes by cohesin. Genome Res. 25, 504-513 (2015).
35. Seitan, V. C. et al. Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments. Genome Res. 23, 2066-2077 (2013).
36. Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307-319 (2013).
37. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-D1006 (2014).
38. Cowper-Sal lari, R. et al. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 44, 1191-1198 (2012).
39. Ongen, H. et al. Putative cis-regulatory drivers in colorectal cancer. Nature 512, 87-90 (2014).
40. Rada-Iglesias, A. et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470, 279-283 (2011).
41. Zentner, G. E., Tesar, P. J. & Scacheri, P. C. Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions. Genome Res. 21, 1273-1283 (2011).
42. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576-589 (2010).
43. Gosselin, D. et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159, 1327-1340 (2014).
44. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
45. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
46. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
47. Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669-16674 (2011).
48. Lockwood, W. W., Zejnullahu, K., Bradner, J. E. & Varmus, H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl Acad. Sci. USA 109, 19408-19413 (2012).
49. Shu, S. et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529, 413-417 (2016).
50. Hart, T. et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163, 1515-1526 (2015).
51. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
52. Markowitz, S. D. & Bertagnolli, M. M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449-2460 (2009).
53. Mansour, M. R. et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014).
54. Zhang, X. et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat. Genet. 48, 176-182 (2016).
55. Pott, S. & Lieb, J. D. What are super-enhancers? Nat. Genet. 47, 8-12 (2015).
56. Hnisz, D. et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell 58, 362-370 (2015).
57. Qian, J. et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 159, 1524-1537 (2014).
58. Meng, F.-L. et al. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. Cell 159, 1538-1548 (2014).
59. Willson, J. K., Bittner, G. N., Oberley, T. D.,Meisner, L. F. & Weese, J. L. Cell culture of human colon adenomas and carcinomas. Cancer Res. 47, 2704-2713 (1987).
60. Boyle, A. P. et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 132, 311-322 (2008).
61. Schmidt, D. et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240-248 (2009).
62. Savic, D., Gertz, J., Jain, P., Cooper, G. M. & Myers, R. M. Mapping genome-wide transcription factor binding sites in frozen tissues. Epigenetics Chromatin 6, 30 (2013).
63. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
64. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
65. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
66. Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 14, 178-192 (2013).
67. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842 (2010).
68. Reimand, J., Arak, T. & Vilo, J. g:Profiler-a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res. 39, W307-W315 (2011).
69. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
70. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5, e13984 (2010).
71. COGENT Study. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat. Genet. 40, 1426-1435 (2008).
72. Pittman, A. M. et al. Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. PLoS Genet. 6, e1001126 (2010).
73. Tomlinson, I. P. M. et al. Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet. 7, e1002105 (2011).
74. Figueiredo, J. C. et al. Genome-wide diet-gene interaction analyses for risk of colorectal cancer. PLoS Genet. 10, e1004228 (2014).
75. Zhang, B. et al. Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. Nat. Genet. 46, 533-542 (2014).
76. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
77. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).
78. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).